zawya.com
Cure8 news brief
Why This Matters
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
The approval is supported by Phase 3 trial data showing clinical remission and endoscopic healing at one year and maintenance in many patients through two years.
Who Should Pay Attention
Adults with moderately to severely active Crohn’s disease, patients who have failed or not tolerated prior immunomodulators or biologics, gastroenterologists and other clinicians who treat IBD, and researchers following new IBD therapies.
Study Snapshot
Story typePress release
Evidence typeRegulatory update
Source depthFull source text
What To Know
about the drug: Mirikizumab-mrkz is a biologic that targets the IL-23p19 protein (an IL-23 inhibitor). The reported trial enrolled patients who had inadequate response, loss of response, or intolerance to steroids, immunomodulators (azathioprine, 6-mercaptopurine, methotrexate) and/or biologics (TNF blockers and integrin receptor antagonists).
Common adverse reactions reported included upper respiratory infections, injection-site reactions, headache, arthralgia and elevated liver tests; the label includes warnings about hypersensitivity, infection risk including tuberculosis, hepatotoxicity and immunizations.
Access and coverage: Eli Lilly (manufacturer) says it is working with insurers and health systems to enable access; the press release notes some pharmacy benefit managers have given first-line biologic coverage and Lilly offers patient support programs and copay assistance where eligible.
Keep In Mind
This is a regulatory/press-release summary of FDA approval and trial results reported by the sponsor. While Phase 3 results and extension data are described, the full prescribing information and peer‑reviewed publications should be consulted for detailed safety and efficacy data. Approval in other countries is pending and ongoing studies (VIVID-2 OLE) are continuing.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationzawya.com
Indexed viaBing News
Source typePress release
PublishedJan 21, 2025, 3:28 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.